About Altheus Therapeutics
Altheus Therapeutics is developing Zoenasa Oral Controlled Release and Rectal Gel formulations as front-line therapies for the treatment of inflammatory bowel disease (IBD) with the initial focus on ulcerative colitis (UC). Zoenasa is a fixed-dose combination of the anti-inflammatory mesalamine (5-aminosalicylic acid; 5-ASA) plus an antioxidant to reduce bowel injury associated with IBD. Zoenasa is formulated as a rectal gel enema to improve efficacy in patients suffering from left-sided (distal) ulcerative colitis; and as oral formulations with an extended- and delayed-release profile for patients with proximal or extensive colitis.
Missing: Altheus Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Altheus Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Altheus Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Altheus Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest Altheus Therapeutics News
May 1, 2014
Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis Avaxia Biologics, Inc. , a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that primary and secondary objectives were successfully met in a first-in-human Phase 1b clinical trial of AVX-470, an oral anti- TNF bovine polyclonal antibody, in patients with active ulcerative colitis. The primary objective of the trial was to evaluate the safety and tolerability of AVX-470. No treatment-related serious adverse events (SAEs) were observed, and there were no allergic reactions or opportunistic infections. The secondary objectives of the trial were to evaluate the pharmacokinetics and immunogenicity of AVX-470. Pharmacokinetics were assessed by measuring bovine immunoglobulin levels in serum, stool and colon tissues. Immunogenicity was assessed by measuring whether AVX-470 induced a human anti-bovine immunoglobulin antibody (HABA) response in serum. Serum concentrations of bovine immunoglobulin remained within the range of baseline values established in patients before dosing with AVX-470, supporting the hypothesis that AVX-470 acts locally in the gut. As expected, many patients had low concentrations of bovine immunoglobulin in serum at baseline, presumably from dietary exposure. Bovine immunoglobulin was detected in colon tissue, confirming that the antibody can penetrate into the colon tissue in ulcerative colitis patients. Bovine immunoglobulin was also detected in stool and had the ability to bind TNF, confirming that AVX-470 resists digestion in the gut. Finally, treatment with AVX-470 did not cause an increase in HABA in serum, supporting the hypothesis that the antibody will display minimal immunogenicity. The trial also included as exploratory objectives the evaluation of clinical and endoscopic responses and effects on biomarkers. AVX-470 showed consistent trends across multiple clinically important endpoints and reduced serum C reactive protein (CRP) and tissue TNF levels at the highest dose. These efficacy trends are highly encouraging because they were reached with a small number of patients after only four weeks of dosing, as compared to the eight weeks of dosing typically required to see significant effects with ulcerative colitis treatments. “Results from our first clinical trial with AVX-470 exceeded our expectations. AVX-470 was well tolerated with no safety signals observed, exhibited the pharmacokinetic properties needed for a gut-targeted antibody therapeutic, and did not induce an anti-drug antibody response. In addition, AVX-470 showed consistent efficacy trends for clinical response, clinical remission, and both pharmacodynamic and disease-associated biomarkers,” said Barbara S. Fox, Chief Executive Officer of Avaxia. “With such positive results, we plan to advance AVX-470 into Phase 2 development.” The Phase 1b trial was a double-blind, placebo-controlled, ascending dose study of AVX-470 in active ulcerative colitis patients. This was the first human study of AVX-470. Three different dose levels of AVX-470 were administered for a period of 28 days. The study involved 14 trial centers in the U.S., Canada, Belgium and Hungary. A total of 36 patients were treated in the trial, with nine patients receiving placebo and 27 patients receiving the drug. The trial was completed in December 2013. Avaxia plans to disclose detailed study results at upcoming scientific meetings or in a peer-reviewed publication. About Inflammatory Bowel Disease Inflammatory bowel disease (IBD) is a serious disease affecting more than 2.5 million people. IBD refers to two related but different diseases: ulcerative colitis and Crohn's disease. These diseases cause chronic inflammation of the intestinal tract, resulting in a significant reduction in quality of life and the risk of life-threatening complications and diseases, including cancer. As a chronic autoimmune disease, IBD is characterized by periods of active disease that alternate with periods of disease control (remission). The annual worldwide market for IBD medications exceeds $4.5 billion, approximately $2.5 billion of which represents sales of currently marketed anti-TNF antibodies. About AVX-470 AVX-470 is the first gut-targeted anti-TNF antibody in clinical development. The lead indication is inflammatory bowel disease (IBD). Currently marketed anti-TNF drugs are highly effective for the treatment of IBD. However, despite their success, these drugs have two significant drawbacks. One is that they must be injected, whereas patients prefer oral medications. More importantly, they cause rare but serious side effects, such as risk of serious infection, because they dampen the immune system throughout the body, not just in the intestines where the disease occurs. As a result, these drugs are used mostly as a second- or third-line therapy, despite evidence that earlier use may improve patient outcomes. In contrast, AVX-470 is an orally administered antibody therapeutic that targets the gut, potentially improving safety and efficacy over existing anti-TNF therapies. Avaxia believes that AVX-470 has the potential to become a first-line therapy that transforms the treatment of IBD. About Avaxia Biologics Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. AVX-470 offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as celiac disease, metabolic disease and GI acute radiation syndrome. www.avaxiabiologics.com Avaxia Biologics: Barbara S. Fox, Ph.D., 781-861-0062 Chief Executive Officer
Altheus Therapeutics Frequently Asked Questions (FAQ)
When was Altheus Therapeutics founded?
Altheus Therapeutics was founded in 2006.
Where is Altheus Therapeutics's headquarters?
Altheus Therapeutics's headquarters is located at 755 Research Parkway, Oklahoma City.
What is Altheus Therapeutics's latest funding round?
Altheus Therapeutics's latest funding round is Series B - III.
How much did Altheus Therapeutics raise?
Altheus Therapeutics raised a total of $16.13M.
Who are the investors of Altheus Therapeutics?
Investors of Altheus Therapeutics include Prolog Ventures, Stifel Financial, SeedStep Angels, Sevin Rosen Funds, i2E and 7 more.
Who are Altheus Therapeutics's competitors?
Competitors of Altheus Therapeutics include Aquinox Pharmaceuticals, Intarcia Therapeutics, Arteriocyte, Nora Therapeutics, Sorbent Therapeutics, CNSBio, Amorcyte, Resolvyx Pharmaceuticals, Nuon Therapeutics, Calixa Therapeutics and 12 more.
Compare Altheus Therapeutics to Competitors
Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.
Inflabloc Pharmaceuticals, Inc. is engaged in the research and development of pharmaceutical treatments for inflammatory disorders. Inflabloc's current product development is based on its discoveries of strong anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. The company's lead product line is a DHEA combination treatment. The company has 4 products in development. IP-1001 is slated to enter Phase 2 clinical trials in Crohn's disease later this year. IP-1002 has completed Phase 1. IP-1003 recently established proof-of-concept in an inflammatory bowel disease (IBD) animal model, while IP-1005 has just entered proof-of-concept testing in a C-reactive protein (CRP) mouse model.
Marval Biosciences is an early stage company, developing contrast agents for use in X-ray and Computed Tomography (CT) Imaging. Marval's lead candidate, NCTX, targets cardiovascular imaging.
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.